RRRanju Ralhan

Ranju Ralhan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ranju Ralhan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Meera Mathur

    Department of Pathology, Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

    5 shared publications
  • Nootan Kumar Shukla

    Surgical Oncology Unit, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

    4 shared publications
  • Sonia Arora

    Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India Fax: +91-11-6862663

    3 shared publications
  • A Srivastava

    Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India

    2 shared publications
  • Jasbir Kaur

    Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India

    2 shared publications
  • Jatinder Kaur

    Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India

    2 shared publications

Latest Publications

  • Alterations in expression of retinoid receptor β and p53 in oral submucous fibrosis

    by J Kaur, N Chakravarti, M Mathur, A Srivastava, R Ralhan

    Objective:  Knowledge of the molecular pathogenesis of oral submucous fibrosis (OSF), a potentially malignant condition with high risk of transition to oral cancer, is meagre. Alterations in the expression of retinoic acid receptor β (RARβ) and tumor suppressor gene, p53 are early events in oral tumorigenesis. The aim of this study was to investigate the alterations in the expression of RARβ and p53 in OSF lesions and determine their association with disease pathogenesis.Methods:  The expression of RARβ and p53 proteins was analyzed by immunohistochemistry in 50 cases of OSF and 30 histologically normal oral tissues.Results:  No detectable RARβ expression was observed in 35 of 50 (70%) OSF cases. p53 protein accumulation was observed in 24 of 50 (48%) OSF cases analyzed. Thirty‐six percent OSF lesions showed loss of RARβ and p53 overexpression. Interestingly, 41 of 50 (82%) of OSF lesions showed altered expression of at least one of these two proteins.Conclusion:  Altered expression of either RARβ or p53 in majority of OSF lesions suggests their association with disease pathogenesis and warrants follow‐up to determine whether OSF lesions harboring concomitant alterations in RARβ and p53 are at a high risk of transition to malignancy.


  • Alterations in cyclin D1 expression in esophageal squamous cell carcinoma in the Indian population

    by Robin Mathew, Sonia Arora, Rinu Khanna, Nootan Kumar Shukla, Meera Mathur, Ranju Ralhan

    Purpose: The p16/cyclin D1/pRb pathway plays a critical role in tumourigenesis. We recently reported alterations in expression of tumour suppressor gene products, p16 and pRb in esophageal cancer. Knowledge of alterations in cyclin D1, a vital component of this pathway in esophageal carcinomas from the Indian subcontinent, where the etiology and pathogenesis may be confounded by various unique dietary and environmental factors, is presently scanty. In order to bridge the gap between the accentuating incidence of esophageal cancer and aberrations in the components of this vital pathway, we analysed cyclin D1 expression in esophageal squamous cell carcinoma in the Indian population. Method: Immunohistochemical analysis of cyclin D1 expression was carried out in paraffin-embedded sections of surgically resected esophageal squamous cell carcinomas (ESCC) (70 patients) and matched with histopathologically normal esophageal tissues from a distant site. The findings were correlated with clinicopathological parameters. Results: Overexpression of cyclin D1 was observed in the tumour nuclei in 41 out of 70 (59%) patients. We found concomitant alterations in 16 and cyclin D1 (p16−/CycD1+ phenotype) in 16 of the 70 patients (23%), while alterations of pRb and cyclin D1 (pRb−/CycD1+) were observed in 36 of the 70 (51%) patients of ESCCs. Cyclin D1 overexpression was significantly associated with the loss of p16 immunoreactivity (P=0.005). The pRb− and p16−/pRb−/Cyc D+ phenotypes showed significant association with differentiation of the tumour (P=0.005, 0.05, respectively). Kaplan-Meier analysis for disease recurrence showed increased disease recurrence in cyclin D1 overexpressed patients. Median time to disease recurrence in the cyclin D1+ group was 15 months as against 18 months observed in the cyclin D1− patients (P=0.067; log-rank test). Conclusion: Alterations in at least one of the components of the p16/cyclin D1/pRb pathway in majority of the 70 patients analysed herein, and concomitant alterations in all the three proteins in 19 patients (35%) underscore the critical role of this pathway in esophageal tumourigenesis. The results of the present study taken together with our previous findings on p16 and pRb alterations in ESCCs suggest that these alterations are not mutually exclusive and may cooperatively provide greater tumour growth advantage. The prognostic significance of alterations in the expression of these components cyclin D1, p16, and pRb remains to be established in a larger cohort.


  • Frequent alterations in the expression of tumor suppressor genes p16 INK4A and pRb in esophageal squamous cell carcinoma in the Indian population

    by Ranju Ralhan, Robin Mathew, Sonia Arora, Rimple Bahl, Nootan Kumar Shukla, Meera Mathur

    Purpose: Alterations in the cell cycle regulatory p16INK4a/Cyclin D1/pRb pathway play a pivotal role in tumorigenesis. Knowledge of alterations in the tumor suppressor protein pRb and its negative regulator, p16CDKN2/MTS1/INK4a in esophageal squamous cell carcinoma (ESCC) from the Indian subcontinent is meager. To gain insight into the mechanisms underlying tumorigenesis and to search for diagnostic molecular markers for ESCC, we analyzed the expression of p16INK4a and pRb in ESCCs in the Indian population. Methods: Immunohistochemical analysis of pRb and p16INK4a proteins was carried out in paraffin-embedded sections from 61 surgically resected ESCCs and matched normal tissues, and the results correlated with clinicopathological parameters using chi square and Fisher's exact tests. Dual immunohistochemical analysis has been carried out to demonstrate the concomitant loss of expression of p16INK4a and pRb. Results: Fifty-nine of 61 (97%) cases showed aberration(s) in either or both of these proteins confirming their critical role in esophageal tumorigenesis. Loss of pRb was observed in 51 of the 61 (84%) and loss of p16INK4a was observed in 35 of 61 (57%) cases. Loss of pRb showed significant association with dedifferentiation of the tumor (P=0.004). p16−/pRb−, and p16+/pRb− phenotypes were significantly associated with nodal metastasis (P=0.017 and 0.027, respectively), while p16−/pRb+ phenotype was associated with dedifferentiation of the tumor (P=0.012). Conclusion: pRb/p16INK4a pathway plays a critical role in esophageal tumorigenesis in the Indian population. The dual hits (concomitant loss) of pRb and p16INK4a expression suggest that these two components are not mutually exclusive, and can both be altered in a significant proportion of primary ESCCs serving as putative diagnostic markers for esophageal cancer. However, the impact of dual hit on tumor behavior and disease prognosis remains to be determined.


    • 1 June 2000
      • Vol. 6  (6) , 2440-7

    Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.

    by R Ralhan, S Agarwal, M Mathur, B Wasylyk, A Srivastava

    The cyclin-dependent kinase inhibitor gene p21(Waf1/Cip1) plays a central role in inducing cellular growth arrest, terminal differentiation, and apoptosis. Alterations in this gene may adversely affect regulation of these processes and increase susceptibility for cancer. We have recently reported a novel polymorphism in the p21(Waf1/Cip1) gene in the Indian population and its association with esophageal cancer. An A-->G transition at codon 149 resulted in amino acid substitution from aspartate to glycine in the proliferating cell nuclear antigen binding COOH-terminal domain of p21(Waf1/Cip1) that may affect PCNA-p21(Waf1/Cip1) interactions, thereby affecting regulation of cellular proliferation, and may increase susceptibility for development of cancer. In a parallel study in our laboratory, we searched for putative p21(Waf1/Cip1) mutations in oral premalignant and malignant lesions. No somatic mutation was detected in exon 2 of p21(Waf1/Cip1). Interestingly, a codon 149 polymorphism variant (A-->G) was identified in 11 of 30 (37%) premalignant lesions (7 of 19 hyperplastic lesions and 4 of 11 dysplastic lesions) and 11 of 30 (37%) squamous cell carcinomas (SCCs). This codon 149 variant was also identified in paired lymphocytes of all of the patients with premalignant lesions and SCCs harboring the variant allele, suggesting the occurrence of a polymorphism. Lymphocyte DNA isolated from 50 unrelated age- and gender-matched healthy subjects was screened for this polymorphism. Seven of 50 (14%) normal controls harbored the A-->G codon 149 variant allele. Immunohistochemical analysis of p21(Waf1/Cip1) protein expression showed immunoreactivity in 19 of these 30 (63%) oral premalignant lesions and 16 of 30 (53%) SCCs. The most intriguing features of the study were: (a) the significant increase in frequency of this polymorphism not only in patients with oral SCCs (P = 0.038), but also in patients with premalignant lesions (P = 0.038), compared with normal controls; and (b) the significantly higher frequency of p21(Waf1/Cip1) variants (codon 149) in oral premalignant lesions (10 of 11 cases) and SCCs (11 of 11 cases) with wild-type p53 (P = 0.045) than in lesions with p53 mutations, suggesting that this polymorphism affects the p53 pathway and may play a vital role in oral tumorigenesis. Furthermore, overexpression of p21 protein in oral lesions harboring missense mutations in the p53 gene suggest a p53-independent role for p21 in the pathogenesis of oral cancer.


  • Open Access

    Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India

    by Ranju Ralhan, Sonia Arora, Tushar Kant Chattopadhyay, Nootan Kumar Shukla, Meera Mathur

    Esophageal cancer (EC) in the Indian population presents in advanced stages with poor prognosis and warrants the identification of a non‐invasive marker for early detection and better prognostic assessment. We have previously reported high prevalence of p53 protein accumulation in esophageal squamous‐cell carcinomas (ESCCs). The present study was designed to determine (i) if esophageal cancer patients elicit a humoral immune response to intra‐tumoral p53 protein accumulation and (ii) their relationship with p53 gene mutations. The goal was to compare the cellular events, p53 protein accumulation and gene mutations with the presence of serum anti‐p53 antibodies (p53‐Abs) and to assess the utility of serological p53‐Ab analysis as a surrogate marker for p53 alterations in esophageal cancer. A high prevalence of circulating p53‐Abs was observed in 36 of 60 (60%) ESCC patients. In a subset of 44 ESCCs, exons 5–9 of the p53 gene were examined for mutations by PCR and direct sequencing of PCR products. Mutational data have been correlated with p53‐Abs and p53 protein accumulation in ESCCs. Circulating p53‐Abs in ESCC patients were significantly associated with intra‐tumoral p53 protein accumulation (p=0.0005). A strong correlation observed between humoral immune response against p53 protein, missense gene mutations and protein accumulation warrants the application of serological p53‐Abs as a non‐invasive surrogate marker in screening high‐risk populations for early detection of malignancy. Int. J. Cancer 85:791–795, 2000.


  • Expression of RAR? and RAR? in human oral potentially malignant and neoplastic lesions

    by Nitin Chakravarti, Meera Mathur, Sudhir Bahadur, Nootan Kumar Shukla, Cecile Rochette-Egly, Ranju Ralhan

    Retinoids reverse potentially malignant lesions and inhibit the development of second primary cancers in patients with head-and-neck cancer. Many of the effects of retinoids result from modulation of gene expression by 2 distinct classes of nuclear receptor, RARs and RXRs; alterations in their expression can lead to tumorigenesis. To determine whether aberrations in expression of the receptors are related to the development of betel- and tobacco-related oral cancer, we used specific monoclonal antibodies against RARα and RARβ to detect expression of these proteins in 30 histopathologically normal tissues, 45 potentially malignant lesions (leukoplakia) with histological evidence of either hyperplasia (31 cases) or dysplasia (14 cases) and 64 oral squamous-cell carcinomas (SCCs) by immunohistochemistry. Of the 30 normal oral tissues analysed, 8 cases showed detectable levels of RARα protein, while 10 cases did not show detectable RARβ immunoreactivity. Immunostaining for RARα protein was observed in 12/31 (39%) hyperplastic lesions, 6/14 (43%) dysplastic lesions and 43/64 (67%) oral SCCs. Expression of RARα in oral SCC was significantly associated with the histological differentiation status of tumours (p = 0.016). In contrast, lack of detectable immunoreactivity was observed in 19/31 (61%) hyperplastic lesions, 8/14 (57%) dysplastic lesions and 21/64 (33%) oral SCCs. The hallmark of the study was the significant increase in RARα immunopositivity in oral SCCs compared to normal tissue (p = 0.0005) and hyperplastic lesions (p = 0.016). One intriguing feature was the significant decrease in RARβ immunopositivity in hyperplastic lesions compared with normal oral mucosa (p = 0.05) as well as in oral SCCs compared with normal tissues (p = 0.0008). Int. J. Cancer 91:27–31, 2001.


  • Open Access

    P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis

    by Ranju Ralhan, Rajeeb K. Swain, Sandhya Agarwal, Jasbir Kaur, Neera Nath, Gautam Sarkar, Meera Mathur, Nootan K. Shukla


  • Prognostic significance of p53 protein overexpression in betel- and tobacco-related oral oncogenesis

    by Jasbir Kaur, Anurag Srivastava, Ranju Ralhan

    We have previously reported overexpression of p53 protein in tobacco‐related oral dysplasia and squamous cell carcinoma (SCC) in the Indian population. A follow‐up study was carried out to determine the prognostic significance of an accumulation of p53 protein during oral tumorigenesis. One hundred and two of 145 (70%) of oral SCCs and 39/75 (52%) of oral dysplasias showed overexpression of p53 protein, while only 3 of 107 (3%) normal oral tissues showed a detectable level of the protein. Follow‐up studies of these patients suggest that an accumulation of p53 protein may be involved in the early phases of oral SCC development and indicate the predisposition of a particular premalignant lesion towards malignancy. In patients with premalignant lesions, the median transition time (premalignancy to malignancy) was significantly shorter in p53 positive cases than in p53 negative cases (p = 0.013). Among the oral cancer patients, univariate analysis showed that alteration in p53 expression was associated with significantly decreased disease‐free survival. The p53 positive cases showed decreased median disease‐free survival time (no recurrence/metastasis) compared with the p53 negative cases (p = 0.013), indicating that p53 accumulation may serve as a prognostic indicator in oral cancer patients. Int. J. Cancer (Pred. Oncol.) 79:370–375, 1998.